Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7135300 | 1.00 | ALDH1A1 (0.51) | ALDH1A1HPGDGLARECQLLMNA | |
| SCHEMBL11831626 | 0.91 | ALDH1A1 (0.52) | ALDH1A1HPGDGLARECQLLMNA | |
| SCHEMBL1799002 | 0.91 | ALDH1A1 (0.52) | ALDH1A1HPGDGLARECQLLMNA | |
| SCHEMBL7291572 | 0.80 | ACE (0.49) | ALDH1A1HPGDGLARECQLKMT2A | |
| SCHEMBL23343853 | 0.80 | ALDH1A1 (0.53) | ALDH1A1HPGDGLARECQLKMT2A | |
| SCHEMBL17787724 | 0.80 | ALDH1A1 (0.53) | ALDH1A1HPGDGLARECQLKMT2A | |
| SCHEMBL8901282 | 0.80 | ALDH1A1 (0.53) | ALDH1A1HPGDGLARECQLKMT2A | |
| SCHEMBL11844024 | 0.78 | ALDH1A1 (0.48) | ALDH1A1HPGDGLALMNASMN1; SMN2 | |
| SCHEMBL8903845 | 0.78 | ALDH1A1 (0.51) | ALDH1A1HPGDGLARECQLKMT2A | |
| SCHEMBL13991694 | 0.78 | ALDH1A1 (0.51) | ALDH1A1HPGDGLARECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | ALDH1A1 3165/4885HPGD 1794/4885GLA 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.